Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H23N5O5 |
| Molecular Weight | 437.4485 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]1(NC(=O)N(CC(=O)N[C@@H](CC(O)=O)C2=CC=CC=C2)C1=O)C3=CC=C(C=C3)C(N)=N
InChI
InChIKey=BQTUWUXJPAYSPB-AOMKIAJQSA-N
InChI=1S/C22H23N5O5/c1-22(15-9-7-14(8-10-15)19(23)24)20(31)27(21(32)26-22)12-17(28)25-16(11-18(29)30)13-5-3-2-4-6-13/h2-10,16H,11-12H2,1H3,(H3,23,24)(H,25,28)(H,26,32)(H,29,30)/t16-,22-/m0/s1
Carafiban is orally active heterocyclic peptide mimetics fibrinogen IIb/IIIa receptor antagonist with antithrombotic activity. Carafiban is a prodrug, that underwent metabolic transformation to active metabolite des-ethyl- Carafiban, that inhibited dose-dependently and reversibly human platelet aggregation. In conscious dogs, Carafiban showed a high plasma availability of the active moiety of 42±8% and a plasma half-life of 9.9 h after oral administration as measured by bioassay. Carafiban may potentially be used for chronic treatment and prophylaxis of thrombotic diseases in humans.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9912737
Created by
admin on Sat Dec 16 19:49:54 UTC 2023 , Edited by admin on Sat Dec 16 19:49:54 UTC 2023
|
PRIMARY | |||
|
170565-45-4
Created by
admin on Sat Dec 16 19:49:54 UTC 2023 , Edited by admin on Sat Dec 16 19:49:54 UTC 2023
|
PRIMARY | |||
|
Q9GG3H64D2
Created by
admin on Sat Dec 16 19:49:54 UTC 2023 , Edited by admin on Sat Dec 16 19:49:54 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
